AstraZeneca
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
AstraZeneca Downsizing R&D Staff
AstraZeneca Downsizing R&D Staff
Kate Yandell | Mar 19, 2013
Positions for 1,600 scientists at the pharmaceutical company will be eliminated globally.